- Conditions
- Acute Coronary Syndrome
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Harvey Hahn
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Kettering, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Vonicog Alfa, ADVATE
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, dose level 1, dose level 2, dose level 3, dose level 4
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Ormond Beach, Florida • Duncansville, Pennsylvania
- Conditions
- Candidemia
- Interventions
- Anidulafungin, Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 24
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 7 more
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2033
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Iron Deficiency, Restless Leg Syndrome
- Interventions
- Probiotics, Placebo
- Dietary Supplement
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Myelodysplastic Syndromes
- Interventions
- CPX-351, Research skin biopsy, Research blood draw, Research bone marrow aspirate
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Tampa, Florida • St Louis, Missouri • Seattle, Washington
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 13
- States / cities
- San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more
- Conditions
- PHA1A
- Interventions
- Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
- Drug
- Lead sponsor
- SAb Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza, Human, COVID-19
- Interventions
- bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,019 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 59
- States / cities
- Athens, Alabama • Phoenix, Arizona • Lake Forest, California + 40 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab, Stereotactic Radiosurgery
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- LET, Laceration of Skin
- Interventions
- LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application), LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)
- Drug
- Lead sponsor
- Children's Hospital of Orange County
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- GBM, Glioblastoma, Glioma, Malignant Glioma
- Interventions
- Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
- Biological
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Siltuximab, Spartalizumab
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiothoracic Surgery, Vascular Surgery
- Interventions
- Placebo, ABT-719
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 16 more
- Conditions
- Amyloidosis
- Interventions
- Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- CD33CART autologous, CD33CART allogeneic
- Biological
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2039
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Bethesda, Maryland + 3 more
- Conditions
- Breast Cancer, DCIS
- Interventions
- HER-2 Pulsed Dendritic cell Vaccine
- Biological
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
- Radiation · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- APOL1-Mediated Kidney Disease
- Interventions
- AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
- Combination Product · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
- Conditions
- Prostate Cancer
- Interventions
- Silibin-Phytosome
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypertension
- Interventions
- COREG CR and lisinopril (FDC)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Tazemetostat, Pembrolizumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Dysfunctional Uterine Bleeding
- Interventions
- Medroxyprogesterone 17-Acetate, medroxyprogesterone acetate
- Drug
- Lead sponsor
- Women's Health Care Clinic, Torrance, California
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Torrance, California